Imaging the inflammatory activity of sarcoidosis

European Respiratory Journal

Volumn 41, Issue 3, 2013, Pages 743-751

  Keijsers, Ruth G M ^a   Van Den Heuve, Daniel A F ^a   Grutters, Jan C ^a,b  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

18F FDG positron emission tomography computed tomography; High resolution computed tomography; Inflammation; Sarcoidosis activity

Indexed keywords

DIAZEPAM; DIPEPTIDYL CARBOXYPEPTIDASE; FLUORODEOXYGLUCOSE F 18; FUROSEMIDE; GADOLINIUM PENTETATE; GALLIUM CITRATE GA 67; HEPARIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR; METHOTREXATE; PENTETREOTIDE IN 111; PREDNISONE; SOMATOSTATIN RECEPTOR; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; CARDIAC SARCOIDOSIS; CARDIOVASCULAR MAGNETIC RESONANCE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; FORCED EXPIRATORY VOLUME; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG DIFFUSION CAPACITY; LUNG SARCOIDOSIS; LUNG SCINTISCANNING; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY; THORAX RADIOGRAPHY; VITAL CAPACITY; WHOLE BODY SCANNER;

FLUORODEOXYGLUCOSE F18; GALLIUM RADIOISOTOPES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOGRAPHY, THORACIC; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; SARCOIDOSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84875248454     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00088612     Document Type: Article

References (78)

1. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007; 357: 2153-2165.
2. Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164: 1885-1889.
3. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 149-173.
4. Judson MA, Baughman RP, Teirstein AS, et al. Defining organ involvement in sarcoidosis: The ACCESS proposed instrument. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 75-86.
5. Consensus conference: Activity of sarcoidosis. Third WASOG meeting, Los Angeles, USA, September 8-11, 1993. Eur Respir J 1994; 7: 624-627.
6. Braun JJ, Kessler R, Constantinesco A, et al. 18F-FDG PET/CT in sarcoidosis management: Review and report of 20 cases. Eur J Nucl Med Mol Imaging 2008; 35: 1537-1543.
7. Keijsers RG, Verzijlbergen FJ, Oyen WJ, et al. 18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis. Eur J Nucl Med Mol Imaging 2009; 36: 1131-1137.
8. Teirstein AS, Machac J, Almeida O, et al. Results of 188 wholebody fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 2007; 132: 1949-1953.
9. Scadding JG. Prognosis of intrathoracic sarcoidosis in England: A review of 136 cases after five years observation. BMJ 1961; 2: 1165-1172.
10. Grenier P, Chevret S, Beigelman C, et al. Chronic diffuse infiltrative lung disease: Determination of the diagnostic value of clinical data, chest radiography, and CT and Bayesian analysis. Radiology 1994; 191: 383-390.
11. Akira M, Kozuka T, Inoue Y, et al. Long-term follow-up CT scan evaluation in patients with pulmonary sarcoidosis. Chest 2005; 127: 185-191.
12. Brauner MW, Lenoir S, Grenier P, et al. Pulmonary sarcoidosis: CT assessment of lesion reversibility. Radiology 1992; 182: 349-354.
13. Lynch DA, Webb WR, Gamsu G, et al. Computed tomography in pulmonary sarcoidosis. J Comput Assist Tomogr 1989; 13: 405-410.
14. Remy-Jardin M, Giraud F, Remy J, et al. Pulmonary sarcoidosis: Role of CT in the evaluation of disease activity and functional impairment and in prognosis assessment. Radiology 1994; 191: 675-680.
15. Wells AU, Rubens MB, du Bois RM, et al. Serial CT in fibrosing alveolitis: Prognostic significance of the initial pattern. AJR Am J Roentgenol 1993; 161: 1159-1165.
16. Wells AU, Rubens MB, du Bois RM, et al. Functional impairment in fibrosing alveolitis: Relationship to reversible disease on thin section computed tomography. Eur Respir J 1997; 10: 280-285.
17. Weiner R, Hoffer PB, Thakur ML. Lactoferrin: Its role as a Ga-67-binding protein in polymorphonuclear leukocytes. J Nucl Med 1981; 22: 32-37.
18. Gupta RG, Bekerman C, Sicilian L, et al. Gallium 67 citrate scanning and serum angiotensin converting enzyme levels in sarcoidosis. Radiology 1982; 144: 895-899.
19. Johnson DG, Johnson SM, Harris CC, et al. Ga-67 uptake in the lung in sarcoidosis. Radiology 1984; 150: 551-555.
20. Kohn H, Klech H, Mostbeck A, et al. 67Ga scanning for assessment of disease activity and therapy decisions in pulmonary sarcoidosis in comparison to chest radiography, serum ACE and blood Tlymphocytes. Eur J Nucl Med 1982; 7: 413-416.
21. Nishiyama Y, Yamamoto Y, Fukunaga K, et al. Comparative evaluation of 18F-FDG PET and 67Ga scintigraphy in patients with sarcoidosis. J Nucl Med 2006; 47: 1571-1576.
22. Prager E, Wehrschuetz M, Bisail B, et al. Comparison of 18F-FDG and 67Ga-citrate in sarcoidosis imaging. Nuklearmedizin 2008; 47: 18-23.
23. Baughman RP, Shipley R, Eisentrout CE. Predictive value of gallium scan, angiotensin-converting enzyme level, and bronchoalveolar lavage in two-year follow-up of pulmonary sarcoidosis. Lung 1987; 165: 371-377.
24. Klech H, Kohn H, Kummer F, et al. Assessment of activity in sarcoidosis. Sensitivity and specificity of 67Gallium scintigraphy, serum ACE levels, chest roentgenography, and blood lymphocyte subpopulations. Chest 1982; 82: 732-738.
25. Beaumont D, Herry JY, Sapene M, et al. Gallium-67 in the evaluation of sarcoidosis: Correlations with serum angiotensinconverting enzyme and bronchoalveolar lavage. Thorax 1982; 37: 11-18.
26. Lieberman J, Schleissner LA, Nosal A, et al. Clinical correlations of serum angiotensin-converting enzyme (ACE) in sarcoidosis. A longitudinal study of serum ACE, 67gallium scans, chest roentgenograms, and pulmonary function. Chest 1983; 84: 522-528.
27. Rizzato G, Blasi A. A European survey on the usefulness of 67Ga lung scans in assessing sarcoidosis. Experience in 14 research centers in seven different countries. Ann NY Acad Sci 1986; 465: 463-478.
28. Israel HL, Albertine KH, Park CH, et al. Whole-body gallium 67 scans. Role in diagnosis of sarcoidosis. Am Rev Respir Dis 1991; 144: 1182-1186.
29. Sulavik SB, Spencer RP, Weed DA, et al. Recognition of distinctive patterns of gallium-67 distribution in sarcoidosis. J Nucl Med 1990; 31: 1909-1914.
30. Sulavik SB, Spencer RP, Palestro CJ, et al. Specificity and sensitivity of distinctive chest radiographic and/or 67Ga images in the noninvasive diagnosis of sarcoidosis. Chest 1993; 103: 403-409.
31. Radiation dose to patients from radiopharmaceuticals (addendum 2 to ICRP publication 53). Ann ICRP 1998; 28: 1-126.
32. Stralingsdosimetrie. In: Barneveld PC, van Urk P, eds. Aanbevelingen Nucleaire Geneeskunde. Neer, Kloosterhof acquisitie services, 2007; pp. 459-472.
33. Dalm VA, van Hagen PM, van Koetsveld PM, et al. Expression of somatostatin, cortistatin, and somatostatin receptors in human monocytes, macrophages, and dendritic cells. Am J Physiol Endocrinol Metab 2003; 285: E344-E353.
34. ten Bokum AM, Hofland LJ, de Jong G, et al. Immunohistochemical localization of somatostatin receptor sst2A in sarcoid granulomas. Eur J Clin Invest 1999; 29: 630-636.
35. Somatostatine receptor scintigrafie. In: Barneveld PC, van Urk P, eds. Aanbevelingen Nucleaire Geneeskunde. Neer, Kloosterhof acquisitie services, 2007; pp. 64-67.
36. Kwekkeboom DJ, Krenning EP, Kho GS, et al. Somatostatin receptor imaging in patients with sarcoidosis. Eur J Nucl Med 1998; 25: 1284-1292.
37. Lebtahi R, Crestani B, Belmatoug N, et al. Somatostatin receptor scintigraphy and gallium scintigraphy in patients with sarcoidosis. J Nucl Med 2001; 42: 21-26.
38. Higashi T, Tamaki N, Torizuka T, et al. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med 1998; 39: 1727-1735.
39. Mochizuki T, Tsukamoto E, Kuge Y, et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med 2001; 42: 1551-1555.
40. Shim HK, Lee WW, Park SY, et al. Relationship between FDG uptake and expressions of glucose transporter type 1, type 3, and hexokinase-II in Reed-Sternberg cells of Hodgkin lymphoma. Oncol Res 2009; 17: 331-337.
41. Zhao S, Kuge Y, Mochizuki T, et al. Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. J Nucl Med 2005; 46: 675-682.
42. Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 1994; 35: 1647-1649.
43. Brewer S, McPherson M, Fujiwara D, et al. Molecular imaging of murine intestinal inflammation with 2-deoxy-2-[18F]fluoro-Dglucose and positron emission tomography. Gastroenterology 2008; 135: 744-755.
44. Kubota R, Yamada S, Kubota K, et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: High accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992; 33: 1972-1980.
45. Keijsers RG, Grutters JC, Thomeer M, et al. Imaging the inflammatory activity of sarcoidosis: Sensitivity and inter observer agreement of 67Ga imaging and 18F-FDG PET. Q J Nucl Med Mol Imaging 2011; 55: 66-71.
46. Foley NM, Coral AP, Tung K, et al. Bronchoalveolar lavage cell counts as a predictor of short term outcome in pulmonary sarcoidosis. Thorax 1989; 44: 732-738.
47. Line BR, Hunninghake GW, Keogh BA, et al. Gallium-67 scanning to stage the alveolitis of sarcoidosis: Correlation with clinical studies, pulmonary function studies, and bronchoalveolar lavage. Am Rev Respir Dis 1981; 123: 440-446.
48. Umeda Y, Demura Y, Morikawa M, et al. Prognostic value of dualtime-point 18F-fluorodeoxyglucose positron emission tomography in patients with pulmonary sarcoidosis. Respirology 2011; 16: 713-720.
49. de Geus-Oei LF, van der Heijden HF, Visser EP, et al. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer. J Nucl Med 2007; 48: 1592-1598.
50. De Bruyne S, Van Damme N, Smeets P, et al. Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases. Br J Cancer 2012; 106: 1926-1933.
51. Eschmann SM, Friedel G, Paulsen F, et al. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2007; 34: 463-471.
52. Nahmias C, Hanna WT, Wahl LM, et al. Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET/CT. J Nucl Med 2007; 48: 744-751.
53. Keijsers RG, Grutters JC, van Velzen-Blad H, et al. 18F-FDG PET patterns and BAL cell profiles in pulmonary sarcoidosis. Eur J Nucl Med Mol Imaging 2010; 37: 1181-1188.
54. Drent M, Jacobs JA, De Vries J, et al. Does the cellular bronchoalveolar lavage fluid profile reflect the severity of sarcoidosis? Eur Respir J 1999; 13: 1338-1344.
55. Ziegenhagen MW, Rothe ME, Schlaak M, et al. Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis. Eur Respir J 2003; 21: 407-413.
56. Keijsers RG, Verzijlbergen EJ, van den Bosch JM, et al. 18F-FDG PET as a predictor of pulmonary function in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28: 123-129.
57. Boellaard R, Oyen WJ, Hoekstra CJ, et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging 2008; 35: 2320-2333.
58. Boellaard R, O'Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: Version 1.0. Eur J Nucl Med Mol Imaging 2010; 37: 181-200.
59. Brix G, Lechel U, Glatting G, et al. Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. J Nucl Med 2005; 46: 608-613.
60. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: A clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 1978; 58: 1204-1211.
61. Sekiguchi M, Numao Y, Imai M, et al. Clinical and histopathological profile of sarcoidosis of the heart and acute idiopathic myocarditis. Concepts through a study employing endomyocardial biopsy. I. Sarcoidosis. Jpn Circ J 1980; 44: 249-263.
62. Hiraga H, Yuwai K, Hiroe M. Guidelines for diagnosis of cardiac sarcoidosis: Study report on diffuse pulmonary disease from the Japanese Ministry of Health and Welfare. Tokyo, Japanese Ministry of Health and Welfare, 1993: Pp. 23-24.
63. Vignaux O, Dhote R, Duboc D, et al. Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: A 1-year follow-up study. Chest 2002; 122: 1895-1901.
64. Vignaux O, Dhote R, Duboc D, et al. Detection of myocardial involvement in patients with sarcoidosis applying T2-weighted, contrast-enhanced, and cine magnetic resonance imaging: Initial results of a prospective study. J Comput Assist Tomogr 2002; 26: 762-767.
65. Frayn KN. The glucose-fatty acid cycle: A physiological perspective. Biochem Soc Trans 2003; 31: 1115-1119.
66. Cheng VY, Slomka PJ, Ahlen M, et al. Impact of carbohydrate restriction with and without fatty acid loading on myocardial 18FFDG uptake during PET: A randomized controlled trial. J Nucl Cardiol 2010; 17: 286-291.
67. Ishimaru S, Tsujino I, Takei T, et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 2005; 26: 1538-1543.
68. Langah R, Spicer K, Gebregziabher M, et al. Effectiveness of prolonged fasting 18F-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol 2009; 16: 801-810.
69. Ohira H, Tsujino I, Yoshinaga K. 18F-Fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis. Eur J Nucl Med Mol Imaging 2011; 38: 1773-1783.
70. Okumura W, Iwasaki T, Toyama T, et al. Usefulness of fasting 18FFDG PET in identification of cardiac sarcoidosis. J Nucl Med 2004; 45: 1989-1998.
71. Williams G, Kolodny GM. Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. AJR Am J Roentgenol 2008; 190: W151-W156.
72. Youssef G, Leung E, Mylonas I, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: A systematic review and metaanalysis including the Ontario experience. J Nucl Med 2012; 53: 241-248.
73. Jakoby BW, Bercier Y, Conti M, et al. Physical and clinical performance of the mCT time-of-flight PET/CT scanner. Phys Med Biol 2011; 56: 2375-2389.
74. Bettinardi V, Presotto L, Rapisarda E, et al. Physical performance of the new hybrid PETCT Discovery-690. Med Phys 2011; 38: 5394-5411.
75. Mostard RL, Voo S, van Kroonenburgh MJ, et al. Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis. Respir Med 2011; 105: 1917-1924.
76. Keijsers RG, Verzijlbergen JF, van Diepen DV, et al. 18F-FDG PET in sarcoidosis: An observational study in 12 patients treated with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2008; 25: 143-150.
77. Conti F, Malviya G, Ceccarelli F, et al. Role of scintigraphy with 99mTc-infliximab in predicting the response of intraarticular infliximab treatment in patients with refractory monoarthritis. Eur J Nucl Med Mol Imaging 2012; 39: 1339-1347.
78. Nekolla SG, Martinez-Moeller A, Saraste A. PET and MRI in cardiac imaging: From validation studies to integrated applications. Eur J Nucl Med Mol Imaging 2009; 36: Suppl. 1, S121-S130.